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Abstract
Asthma and allergy are complex disorders influenced by both inheritance and environment, a relationship that might be
further clarified by epigenetics. Neuropeptide S Receptor 1 (NPSR1) has been associated with asthma and allergy and a
study suggested modulation of the genetic risk by environmental factors. We aimed to study DNA methylation in the
promoter region of NPSR1 in relation to asthma and environmental exposures. Electrophoretic Mobility Shift Assay (EMSA)
was used to investigate potential functional roles of both genotypes and methylation status in the NPSR1 promoter. DNA
methylation was analysed using EpiTYPER in blood samples from two well-characterized cohorts; the BIOAIR study of severe
asthma in adults and the Swedish birth cohort BAMSE. We observed that DNA methylation and genetic variants in the
promoter influenced the binding of nuclear proteins to DNA, suggesting functional relevance. Significant, although small,
differences in methylation were related to both adult severe asthma (p= 0.0001) and childhood allergic asthma (p= 0.01).
Furthermore, DNA methylation was associated with exposures such as current smoking in adults for two CpG sites (p= 0.005
and 0.04), parental smoking during infancy in the children (p= 0.02) and in which month the sample was taken (p= 0.01). In
summary, DNA methylation levels in the promoter of NPSR1 showed small but significant associations with asthma, both in
adults and in children, and to related traits such as allergy and certain environmental exposures. Both genetic variation and
the methylated state of CpG sites seem to have an effect on the binding of nuclear proteins in the regulatory region of
NPSR1 suggesting complex regulation of this gene in asthma and allergy.
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Introduction
Asthma and allergy are complex disorders influenced by both
inheritance and environment. In recent decades there has been a
marked increase in their prevalence that today has reached a
plateau, a development that cannot be explained by genetics
alone. Epigenetics might help to explain this development of
asthma and allergy, but studies on this topic are so far few. DNA
methylation is an epigenetic modification that occurs mostly on
cytosines followed by guanines, so called CpG sites. There are
approximately 28 million such CpG sites in the human genome
and of these, 70 to 80% are methylated [1]. Methylation of DNA
has previously been shown to regulate gene expression [2] and it is
believed that the occurrence of these marks/modifications can be
affected by the environment and that this could partly explain the
increase in the prevalence of asthma and allergy [3]. For example,
exposure to smoking in utero may influence DNA methylation in
the offspring [4], and has been associated with an increased risk of
childhood asthma [5,6]. This effect was also observed in
grandchildren of grandmothers that smoked during the mother’s
fetal period which indicates a transgenerational effect that might
be mediated by a change in DNA methylation patterns.
The Neuropeptide S Receptor 1 (NPSR1) gene on chromosome
7p14.3 encodes a G-protein coupled receptor that has been
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associated to many complex disorders such as asthma, irritable
bowel syndrome, rheumatoid arthritis and psychiatric disorders
[7–12]. The receptor was first identified as an asthma candidate
gene by positional cloning and has since then been replicated
several times in different ethnic populations [10,13–20]. Recent
data suggest that the genetic background of NPSR1 can modify the
effect of environmental factors such as farm exposure on the
development of allergic symptoms [21]. The underlying mecha-
nism of this effect in asthma is still unknown.
Since NPSR1 is a strong candidate gene for asthma and one
study suggested that its genetic risk is modulated by the
environment, we aimed to study DNA methylation in the
regulatory region of NPSR1 in relation to asthma and environ-
mental exposures. We used Electrophoretic Mobility Shift Assay
(EMSA) to investigate a potential functional role of both genotypes
and methylation status in the regulatory region of NPSR1. We used
two well characterized cohorts that offer unique opportunities to
investigate genetics and epigenetics in relation to asthma
phenotypes and environmental exposures; the BIOAIR study of
severe asthma in adults [22] and the Swedish birth cohort BAMSE
[23].
Results
Transcription factor binding sites, DNA methylation, and
genetic variants
The NPSR1 promoter contains twelve CpG sites (Figure 1) [24].
To evaluate potential functionality of these CpG sites, we
performed EMSA to test for possible differential protein binding
based on both genotype and methylation status. Four suggestive
transcription factor binding sites in the promoter were selected
based on the presence of a CpG site within the predicted binding
site. The sites studied included CpG site 2 coinciding with
rs2168890 in a predicted Hmx2 binding site, CpG site 3 in a
predicted STAT1 binding site, CpG site 8 coinciding with
rs2530547 in a predicted binding site for Myb, and CpG site 9
coinciding with rs887020 in a predicted binding site for AP1
(Figure 1). EMSA using nuclear extracts from both Colo205 and
HEK293 cells showed clear differences in binding of nuclear
proteins based both on genotype and methylation status of the C
allele in the CpG site 2/rs2168890 (Figure 2). CpG site 3 showed
differences in binding of nuclear proteins between unmethylated
and methylated cassettes with loss of bands for the methylated
cassette. The results for CpG site 8 showed no or very weak
binding for either allele of the SNP rs2530547 while the
methylated C allele bound nuclear proteins. CpG site 9 showed
loss of protein binding for the C allele, both methylated and
unmethylated, as compared to the T allele (upper band, Figure 2).
Taken together, the EMSA results suggest that DNA methylation,
in the promoter of NPSR1, could functionally be relevant based on
the differential binding of transcription factors due to not only
genetic variation but also the methylated state of the allele creating
a CpG site.
Variation of DNA methylation in main blood cell types
To assess whether it would be meaningful to measure DNA
methylation levels in peripheral blood samples, we compared the
degree of methylation in the NPSR1 region in a set of samples of
whole blood and fractionated white blood cells from six healthy
adult male donors [25]. Three of the probes included in the
Illumina Infinium 450K array for DNA methylation were
overlapping with CpG sites in the NPSR1 promoter region
analyzed here, i.e. CpG sites 3, 7 and 10, described below. The
results show that across NPSR1, the degree of methylation in
different types of white blood cells is relatively constant, suggesting
that methylation measurements are reliable for NPSR1 in whole
blood irrespective the differential count of white blood cells
(Figure 3). Furthermore, to get a more complete picture of the cell
specific DNA methylation pattern in the NPSR1 promoter region,
we use the EpiTYPER technology to determine DNA methylation
levels of CpG site 1–12 in the same samples used for the array
based method (Figure S5). Again, we confirm that the degree of
methylation is similar across different cell types in whole blood for
the promoter region studied in NPSR1.
DNA methylation and genetic variation in the NPSR1
promoter
We next performed a pilot study to evaluate if differences in
DNA methylation status can be identified in whole blood from
patients with asthma and other obstructive airway disease,
including adults with mild asthma, severe asthma or chronic
obstructive pulmonary disease (COPD) from the BIOAIR study
(n= 171, Table 1) and a subset of 260 randomly selected children
with or without asthma from the BAMSE birth cohort. DNA
methylation levels for twelve CpG sites in the promoter region of
NPSR1, approximately 600 base pairs 59 of the transcription start
site (Figure 1) were analysed using EpiTYPER [26]. There was a
difference in both age and gender distribution for the adults in the
BIOAIR study. Patients with COPD were older and consisted of
more males compared to both mild and severe asthmatics
(Table 1). The age and gender distributions among healthy and
asthmatic children were similar between those 260 randomly
chosen from the BAMSE birth cohort (healthy children 8.360.4
years and 52% boys, asthmatic children 8.460.4 years and 61%
boys). The difference between minimum and maximum measured
levels in DNA methylation for all the CpG sites in the promoter
region (Dmax-min) varied from lowest 15% to highest 47% in the
total adult sample set and the total childhood sample set varied
from lowest 10% to highest 52%. Most CpG sites in the promoter
showed very high levels of average methylation (.75%) with the
exception of CpG site 8 showing lower methylation levels (,60%).
There were indications of difference in DNA methylation based on
adult asthma and other obstructive airway disease for CpG site 2
(homozygous C allele carriers only) and CpG site 5 in the
promoter region (Table S1). None of the CpG sites analysed for
the smaller selection of BAMSE samples (n = 260) were differen-
tially methylated between the groups but they showed overall
similar degree of methylation as compared to the adult BIOAIR
samples (Table S1).
Next, we investigated whether SNPs located in the predicted
NPSR1 promoter region were associated with asthma and other
obstructive airway disease in the 171 adult samples from BIOAIR
and the 260 BAMSE children. Four SNPs were genotyped,
rs2168891, rs2168890, rs2530547 and rs887020, which coincide
with CpG sites 1, 2, 8 and 9, respectively (Figure 1). The genotype
distribution for the four SNPs were similar between the groups
(mild asthma vs. severe asthma vs. COPD or healthy vs. asthmatic
children) showing no significant association with asthma in neither
the BIOAIR study nor the BAMSE randomised children (data not
shown). Importantly, we found that the level of DNA methylation
was affected by genotypes in the predicted NPSR1 promoter
region. For example, at CpG site 2 (rs2168890) and CpG site 8
(rs2530547), a step-wise decrease in DNA methylation was
observed depending the CC, CT or TT genotype, respectively.
However, there were no effects on DNA methylation neither for
the rs2168891 at CpG site 1 nor for the rs887020 at CpG site 9.
Only homozygous carriers of the allele creating a CpG site were
DNA Methylation in the NPSR1 Promoter and Asthma
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considered for further analysis both in the BIOAIR and the
BAMSE analysis.
NPSR1 promoter methylation status, asthma and other
obstructive airway disease, lifestyle and exposure in
adults
The BIOAIR study is an extensive collection of data including a
one year follow up of the patients [22] and was therefore sought to
be investigated in more detail with the respect to DNA
methylation, asthma and environmental exposures. The effect of
phenotypes related to asthma and COPD and lifestyle factors
(including BMI and smoking) on DNA methylation of the
predicted NPSR1 promoter region (CpG site 1–12), are shown in
Table 2. For analyses regarding the CpG site 1, 2, 8 and 9, only
homozygous individuals for the allele creating the CpG site were
included due to confounding effects of the SNP on the methylation
analysis (n = 147, 116, 62 and 40, respectively). An adjusted linear
regression model was used to identify associations between DNA
methylation and asthma and other obstructive airway disease.
There was significantly decreased methylation levels for CpG site
5 in severe asthma patients compared to mild asthma patients
when adjusting for age, gender and country of origin (p=0.0001,
Table 2). Current smoking showed largest effects on DNA
methylation levels. CpG site 1 showed significantly increased
levels of methylation in relation to current smoking (p=0.005) but
not to former smoking (p=0.13). For CpG site 8, the effect of
current smoking resulted in 8% change in DNA methylation
(p=0.042) while former smoking resulted in a 6% change
(p=0.013, Table 2). Small but significant changes in the level of
DNA methylation were also linked to BMI for CpG site 2, 3 and 5
and to age for CpG site 4 (p=0.045, Table 2). Given the known
relationship between asthma and obesity/BMI, we also adjusted
the analyses between methylation status at CpG site 5 and severe
asthma for BMI and found the results unchanged (p = 0.002).
However, the association between CpG site 5 and BMI became
non-significant (p = 0.12) after adjustment for asthma status, which
indicates that this effect at CpG site 5 is mediated by asthma status
rather than BMI per se. Results were unchanged between BMI
and CpG sites 2 and 3 after adjustment for affection status. There
were no relationships found between lung function tests (FEV1 and
FVC) or blood eosinophil counts and DNA methylation.
Figure 1. The promoter region of the Neuropeptide S Receptor 1 gene (NPSR1). Polymorphisms are marked by triangles, transcription factor
binding sites are underlined and CpG sites are shaded in gray. Green color of the transcription factor indicates neurologically associated factors, blue
indicates immunologically associated factors, and black indicates general factors.
doi:10.1371/journal.pone.0053877.g001
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NPSR1 promoter methylation status and asthma in
children
Based on the results from EMSA as well as the suggestive
associations between asthma and life style factors, and DNA
methylation in the 59 end of the predicted NPSR1 promoter for the
BIOAIR study, we analysed CpG sites 1 to 5 more in depth in a
larger number of children from the BAMSE study (n= 546). The
children were of the same age but gender distribution differed
among healthy and asthmatic children and asthmatic children
were more frequently exposed to parental smoking in infancy
(Table 3). To answer the question if methylation levels were
associated with childhood asthma, adjusted linear regression was
performed between methylation status and different asthma
outcomes. For analyses regarding the CpG site 1 and 2, only
homozygous individuals for the allele creating the CpG site were
included due to confounding effects of the SNP on the methylation
analysis (n = 470 and 397, respectively). Four models were
considered to test for differences in methylation status between
healthy controls and cases diagnosed with: 1) asthma ever up to 8
years, 2) allergic asthma up to 8 years, 3) non-allergic asthma up to
8 years, and 4) current asthma at 8 years. The results showed a
small, but significantly lower NPSR1 promoter methylation level in
children diagnosed with asthma ever up to age 8 as compared to
healthy children at CpG site 4 (p=0.04, Table 4). Lower DNA
methylation levels of the promoter were also seen in children with
allergic asthma at CpG site 1 (p=0.01) and at CpG site 4 (p=0.04)
as compared to healthy children, whereas no differences were seen
between non-allergic asthmatics and healthy children. The level of
significance remained after adjustment for gender, age at blood
sampling and plate used for sodium bisulfite treatment. The results
showed no significant difference in NPSR1 promoter methylation
levels between children with current asthma as compared to
healthy children. CpG site 5 was not associated with any asthma
outcome in children.
NPSR1 promoter methylation status, lifestyle and
environmental factors in children
Extended analyses of the 59end of the predicted NPSR1
promoter was also performed to test if the methylation status
was affected by lifestyle and environmental factors in children up
to 8 years of age (Table 5). Parental smoking in infancy was
associated with a small, but significantly lower level of DNA
methylation in CpG site 1 (p=0.02, Table 5). However, there was
no significant association to current parental smoking. High
current dietary folate intake was associated with decreases in DNA
methylation levels at CpG site 1 (p=0.01) and CpG site 4
(p=0.04). No association was observed in NPSR1 promoter
methylation in relation to exposure to traffic-NOx during infancy
or currently, or to current BMI (Table 5). Interestingly, a seasonal
effect was found on the DNA methylation status of the predicted
NPSR1 promoter region. A significant increase in DNA methyl-
ation of CpG site 5 was observed for samples obtained during July
to September (p=0.01), and October to December (p=0.02), as
compared to January to March, which was used as reference
category. After additional adjustment for birth month, the
significance remained at CpG site 5 July to September
(p=0.003). Further analyses showed that sensitization to any
inhalant allergen (positive Phadiatop) was associated with
decreased methylation in CpG site 1 (p = 0.01), similar to the
results for allergic asthma (Table 4). Specifically, sensitization to
birch and dog were associated with methylation changes (p = 0.05
and 0.04, respectively).
Discussion
This study presents an extensive analysis of DNA methylation in
the promoter of NPSR1 in relation to asthma, lifestyle and
exposures in both adults and children. We found a functional
relevance of DNA methylation at certain CpG sites in the
promoter based on differential binding of nuclear proteins, an
effect also shown for genetic variants. Furthermore, there were
small but significant differences in DNA methylation in relation to
adult severe asthma (but not COPD) as well as to allergic asthma
in children. Furthermore, we observed associations between DNA
methylation changes in the promoter region and current smoking
in adults and passive smoking in children. The previous genetic
associations seen to IgE levels and allergy in relation to asthma for
NPSR1 polymorphisms [10,14,20,27], in combination with our
results in this study, highlight the importance this gene might have
in the corresponding biology.
Many of the genetic associations concerning NPSR1 and asthma
are related to allergic asthma [10,14,20,27]. Up-regulation of
Npsr1 expression in the lung has been observed in one mouse
model of allergen-induced airway inflammation [10] but not in
other models [28,29]. Low levels of methylation are generally
associated with higher levels of gene expression [2]. We found that
DNA methylation in the predicted NPSR1 promoter was slightly
lower in peripheral blood from children that have allergic asthma
as compared to healthy children. Although it remains to compare
methylation patterns in blood and lung tissue specimens from
subjects with asthma, recent data suggest that the pattern in blood
inflammatory cells reflect those in the lung tissue [30]. It should be
noted that parental report of doctor’s diagnosis of asthma was used
Figure 2. Electric Mobility Shift Assay (EMSA) for four sites in
the promoter for Neuropeptide S Receptor 1 gene (NPSR1). The
experiment was performed three separate times using nuclear protein
extracts from two different cell types (Colo205 and HEK293). Data
presented here is a representative gel using nuclear extract from
Colo205. Data was similar for nuclear cell extracts from both cell lines.
The sites studied included CpG site 2 coinciding with rs2168890 in a
predicted HMX2 binding site, CpG site 3 in a predicted STAT1 binding
site, CpG site 8 coinciding with rs2530547 in a predicted binding site for
MYB, and CpG site 9 coinciding with rs887020 in a predicted binding
site for AP1. Arrows indicates sites showing differential binding.
doi:10.1371/journal.pone.0053877.g002
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Figure 3. Neuropeptide S Receptor 1 gene (NPSR1) DNA methylation levels in isolated cells from peripheral blood. Peripheral blood
donations were obtained from six healthy adult male donors. Data were obtained using the Illumina Infinium 450K bead array and the M-value
represents methylation degree [25]. Dark grey bars represent lymphoid cells, light grey bars myeloid cells and black bar whole blood. TSS –
Transcription start site.
doi:10.1371/journal.pone.0053877.g003
Table 1. Characteristics of the BIOAIR study population (n = 171).
Mild Adult Asthma Severe Adult Asthma COPD p-value
n 56 67 48
Age (years) 41.6613.2 50.3613.2 63.868.5 ,0.05
Gender (% males) 44.6 43.3 75 ,0.05
BMI (kg/m2) 25.263.81 28.765.3 27.465.31 ,0.05
Current smokers (n = 14) 1 2 11 ,0.05
Former smokers (n = 67) 12 18 37
FEV1 (%pred) 87.3618.3 71.4621.4 50.0616.1 ,0.05
FVC (%pred) 104.6616.1 87.5620.61 77.2616.5 ,0.05
Blood eosinophils (109/L) 0.3160.272 0.3760.353 0.2360.293 ns
rs2168891 CC/CT/TT (%) 83.9/14.3/1.8 83.6/16.4/0 91.7/8.3/0 ns
rs2168890 CC/CT/TT (%) 69.1/30.9/01 71.4/28.6/04 73.3/26.7/05 ns
rs2530547 CC/CT/TT (%) 29.1/54.5/16.41 40.9/45.5/13.61 40.4/48.9/.10.61 ns
rs887020 AA/AG/GG (%) 28.6/53.6/17.9 17.9/52.2/29.9 20.8/58.3/20.8 ns
COPD - Chronic Obstructive Pulmonary Disease, BMI – Body Mass Index, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital Capacity. Data are presented
as mean 6 standard deviation. P-values were calculated using ANOVA for continuous variables and chi square test for distributions.
1one individual with missing data,
2five individuals with missing data,
3two individuals with missing data,
4seven individuals with missing data,
5three individuals with missing data.
doi:10.1371/journal.pone.0053877.t001
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Table 3. Characteristics of the BAMSE study population (n = 546).
Controls Asthma ever p-value
n 273 273
Age (years) 8.360.5 8.460.5 ns
Gender (% boys) 48.4 61.5 ,0.05
rs2168891 CC/CT/TT (%) 89.0/11.0/01 88.4/11.6/02 ns
rs2168890 CC/CT/TT (%) 77.3/21.9/0.83 76.9/22.4/0.84 ns
rs2530547 CC/CT/TT (%) 46.9/40.8/12.25 38.6/47.9/13.52 ns
rs887020 AA/AG/GG (%) 16.8/48.4/34.86 21.4/50.8/27.87 ns
Allergic asthma 0 136 na
Non-allergic asthma 0 137 na
Current asthma 0 123 na
Parental smoking in infancy (%) 17.7 26.1 ,0.05
Current parental smoking (%) 17.0 22.6 ns
Current dietary folate intake ( mg/day) 217.0636.9 214.2631.4 ns
Current BMI (kg/m2) 17.161.8 17.362.0 ns
Sampling season of blood samples ns
January-March 87 86
April-June 78 87
July-September 40 38
October-December 68 62
BMI – Body Mass Index, ns – non significant, na – not analyzed. Data are presented as mean 6 standard deviation. P-values were calculated using Student’s T-test for
continuous variables and chi square test for distributions.
1ten individuals with missing data,
2six individuals with missing data,
313 individuals with missing data,
418 individuals with missing data,
511 individuals with missing data,
629 individuals with missing data,
725 individuals with missing data.
doi:10.1371/journal.pone.0053877.t003
Table 4. DNA methylation status compared between asthma cases and controls in the BAMSE cohort (n = 546) using adjusted
linear regression models.
Case (n)
CpG
site
1*
CpG site
2**
CpG
site 3
CpG site
4
CpG site
5
Control (n)
%
mean P{ P{{ % mean P{ P{{
%
mean P{ P{{ % mean P{ P{{ % mean P{ P{{
Methylation level
(min-max %)
83.7–
98.2
61.8–92.4 66.6–
98.3
66.5–88.5 67.8–96.6
Asthma ever case (273) 91.1 0.07 0.08 80.7 0.81 0.93 85.9 0.55 0.53 80.9 0.04 0.05 86.3 0.84 0.79
control (273) 91.4 80.8 86.2 81.4 86.2
Allergic asthma case (136) 90.8 0.01 0.01 80.2 0.27 0.39 85.6 0.31 0.13 80.8 0.04 0.03 86.1 0.67 0.72
control (273) 91.4 80.8 86.1 81.4 86.2
Non-allergic
asthma
case (137) 91.3 0.79 0.62 81.1 0.51 0.35 86.2 0.96 0.81 81.0 0.21 0.20 86.5 0.45 0.44
control (273) 91.4 80.8 86.2 81.4 86.2
Current asthma case (123) 91.2 0.31 0.30 80.7 0.91 0.79 85.8 0.49 0.48 80.9 0.09 0.11 86.8 0.13 0.14
control (273) 91.4 80.8 86.2 81.4 86.2
*Only homozygous carriers of the allele (rs2168891) creating a CpG site were included in the analyses of CpG site 1 (Asthma ever n cases/controls = 236/234, Allergic asthma
n cases/controls = 120/234, Non-allergic asthma n cases/controls = 116/234, Current asthma n cases/controls = 103/234).
**Only homozygous carriers of the allele (rs2168890) creating a CpG site were included in the analyses of CpG site 2 (Asthma ever n cases/controls = 196/201, Allergic
asthma n cases/controls = 94/201, Non-allergic asthma n cases/controls = 201/201, Current asthma n cases/controls = 89/201).
{p-value for crude linear regression model.
{{p-value for linear regression model adjusted for gender, age at blood sampling and plate used for sodium-bisulfite treatment.
doi:10.1371/journal.pone.0053877.t004
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as a basis for all asthma phenotypes in BAMSE, and that the
cohort data did not allow for analyses of e.g. severe asthma in
children as evaluated by a paediatrician. Further studies on other
asthma phenotypes such as severe asthma are warranted.
We identified methylation sites in the promoter for NPSR1 that
showed differential methylation in relation to exposures of
smoking, either current smoking in adults or passive smoking in
children. Several studies have shown effects of smoking on DNA
methylation, both on candidate gene level and globally [31–34].
Interestingly, a previous report from the BAMSE birth cohort
found a dose-response relation between exposure to parental
smoking in infancy and IgE sensitisation [35], supporting a link
between variations in NPSR1 methylation and allergic asthma.
To further support an effect between DNA methylation in
NPSR1 and allergic asthma, we saw an increase in DNA
methylation related to blood sampling during the months July to
December compared to January to March in both asthmatic and
healthy children. Seasonal variation has been shown to influence
DNA methylation at certain genomic regions when considering
prenatal nutritional variation during periods of famine [36,37].
Our data may indicate an environmental effect of, for example,
allergens such as airborne pollen exposure during spring and/or a
greater exposure to certain viruses and other infections during
winter time, both relevant factors for the exacerbation of asthma.
Further studies are however needed to clarify the role of seasonal
effects on methylation patterns.
A methyl-rich diet can affect methylation status and enhance
allergic airway disease in mice offspring [38], and periconceptional
maternal folic acid use is associated with increased methylation in
the growth promoting gene IGF2 [39]. Here we report a decreased
methylation level in the predicted NPSR1 promoter in association
with high dietary folate intake in children. The conflicting results
may partly be explained by the fact that we consider a daily intake
of folate from the diet whereas others have looked at intake from
supplements. Further, compared to others we have investigated
the child’s current intake which might not affect methylation to the
same degree as for example intrauterine exposure. Nevertheless,
our results should be interpreted with caution until further
replicated.
Traffic related air pollution exposure has been linked to incident
airway disease in a previous study in the BAMSE birth cohort [40]
and this effect appeard to be modified by genetic polymorphisms
[41]. Traffic related air pollution has also been reported to affect
DNA methylation [42,43]. We found no effect between NOx from
traffic and methylation in the promoter of NPSR1. The NOx levels
in Stockholm are comparatively low in an international compar-
ison, which may contribute to the absence of association.
In this study, we have focused on asthma and used DNA
derived from peripheral blood as target for analysis. Importantly,
there are several tissues expressing NPSR1 mRNA and protein
such as immune cells, gut, skin and lung epithelium as well as the
brain [9,10,44–47]. Furthermore, NPSR1 has not only been
associated to asthma and related phenotypes but also to other
diseases and target tissues. While the expression of NPSR1 is rather
low in immune cells, in accordance with our finding of high levels
of DNA methylation, other tissues might show larger variations in
both expression and DNA methylation and therefore further,
more detailed studies in various tissues are required in the future.
However, even though peripheral blood is a mixture of many cell
types in different developmental stages we could here show that
the cell specific patterns for DNA methylation regarding NPSR1 in
blood show little variation indicating that using whole blood could
still be relevant. Also, although our data suggest that the region we
have studied is a functional promoter [24], other alternative
promoters may exist that could show cell specificity.
Age is a factor that long has been associated with changes in
DNA methylation [48,49]. It has been shown that genome-wide
DNA methylation generally decreases with age [48,50] but certain
sites also show increased methylation [48]. Furthermore, the rate
of methylation changes in blood may be higher in children
compared to adult populations [48]. In our study we saw some
effects by age on the levels of DNA methylation for certain CpG
sites, specifically for CpG site 3. Here, younger study participants
showed lower levels of methylation when comparing all adults to
all children irrespective of disease (Figure S1).
In summary, DNA methylation levels in the promoter of NPSR1
showed significant associations with asthma and related traits such
as allergy, as well as with certain exposures, when measured in
DNA from whole blood, although absolute differences were
generally small. Importantly, EMSA performed in the same region
suggest that both genetic variation and the methylated state of the
CpG sites have an effect on the binding of transcription factors in
the regulatory region of NPSR1. These results, however, need to be
further evaluated in other target tissues and/or specific cell types
in an independent sample material.
Materials and Methods
Ethical statement
This study was performed in accordance with the principles
expressed in the Declaration of Helsinki. The study was approved
by the local ethics committee at Karolinska Institutet and the
BIOAIR study (clinicaltrials.gov.NCT00555607; EU Contract
QLG1-CT-2000-01185) was approved by the ethics review boards
and drug regulatory authorities in the twelve participating centers
(Stockholm, Athens, Heraklion, Gent, Montpellier, London,
Southampton, Krakow, Palermo, Ferrara, Hamburg and Leiden).
Written informed consent for genetic testing was obtained either
by the adult study participant or from the parents of the
participating children.
Study design
This study was conducted in four steps: 1) a functional study to
evaluate the relevance of DNA methylation in the predicted
NPSR1 promoter, 2) testing of DNA methylation at CpG sites in
the promoter region of NPSR1 in a smaller set of human DNA
samples (both adults and children) obtained from peripheral blood,
and 3) general analysis of all CpG sites in the promoter in relation
to respiratory phenotypes, life style factors and exposures in the
BIOAIR study [22], 4) in depth analysis of CpG sites shown in
previous steps to be of interest for further analysis in a larger data
set from the BAMSE birth cohort [23] which would allow for
studying the influence of environmental exposures.
BIOAIR. The aim of BIOAIR (the BIOmarkers of severe
chronic AIRways disease) study is to clarify the natural course of
severe asthma, elucidate mechanisms, risk factors, markers of
severity, exacerbations and poor outcome [22]. Adult patients with
mild controlled asthma, severe uncontrolled asthma and chronic
obstructive pulmonary disease (COPD) were followed for one
year. Data were collected at baseline and at several visits during
one year of follow up and included: spirometry (FIV1, FEV1, FVC,
FEV1/FVC), clinical characteristics, medical history, induced
sputum, urine, medication use and questionnaires (respiratory
quality of life and asthma control). Blood samples from 56 mild
asthmatics, 67 severe asthmatics and 48 COPD patients were
collected at baseline and DNA was extracted for investigation of
DNA methylation status and genetic variation in NPSR1 (Table 1).
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BAMSE. The BAMSE (Swedish abbreviation for Children
Allergy Environment Stockholm Epidemiology) study is a Swedish
prospective birth cohort [23] with 4,089 infants recruited between
1994 and 1996. Data related to environmental exposures and
symptoms of asthma and allergic diseases in the children have
been obtained by questionnaires sent to the parents at different
occasions. Peripheral blood samples drawn at 8 years of age were
used for analysing serum IgE antibodies to inhalant allergens using
Phadiatop (Phadia AB, Uppsala, Sweden) as well as for the current
study on DNA methylation.
All children in BAMSE with a doctor’s diagnosis of asthma
(ever) up to 8 years of age as reported by the parents, with DNA
available for analyses were selected as cases (n = 273) and children
with no history of asthma or other allergic diseases with DNA
available for analyses were selected as controls (n = 273) [51].
Cases and controls were obtained after exclusion of individuals
with non-successful DNA methylation analyses (n = 19) resulting in
273 cases and 273 controls (Table 3). The pilot study testing the
assays in human peripheral blood derived DNA was based on a
random selection of all the 273 children in BAMSE with a doctor’s
diagnosis of asthma (ever) up to 8 years of age (n = 136) and a
subsequent random selection of the 273 healthy children (n= 124).
For the in depth investigation of DNA methylation status, a
selection of CpG sites (number 1 to 5) were studied in relation to
asthma phenotypes and the effect of exposure to environmental
factors.
Four asthma phenotypes were investigated in relation to DNA
methylation status; 1) asthma up to 8 years of age (doctor’s
diagnosed reported by the parents), 2) allergic asthma (defined as
doctor’s diagnosis of asthma up to 8 years in combination with an
IgE-value for Phadiatop $0.35 kU/l; a mixture of cat, dog, horse,
birch, timothy, mugwort, Dermatophagoides pteronyssinus, and Clado-
sporium allergens), 3) non-allergic asthma (defined as doctor’s
diagnosis of asthma up to 8 years in combination with an IgE-
value for Phadiatop #0.35 kU/l), and 4) current asthma at 8 years
(defined as doctor’s diagnosis of asthma up to 8 years in
combination with at least one episode of wheeze in the last 12
months). In addition, association between sensitization (IgE-value
for Phadiatop $0.35 kU/l) and methylation levels were also
analyzed.
Exposure to environmental tobacco smoke was classified as
parental tobacco smoke exposure in infancy (daily parental
smoking at birth of the child, yes/no) and current parental
tobacco smoke exposure (daily parental tobacco smoke exposure at
child age 8 years, yes/no). Information on air pollution exposure
from road traffic (NOx) at residential, day care, and school
addresses was estimated using dispersion modelling, and has been
described elsewhere [52]. The mean level of traffic-NOx to which
the child was exposed during infancy was 19.5 mg/m3 (median:
15.0 mg/m3 and 5th–95th percentile: 3.2-48.9 mg/m3) and current
mean exposure level at 8 years of age was 9.6 mg/m3 (median:
7.3 mg/m3 and 5th–95th percentile: 1.7–27.7 mg/m3) in the study
population (cases and controls combined). Associations were
investigated for the 5th–95th percentile difference in NOx
exposure levels corresponding to 45.7 mg/m3 during first year of
life (here defined as NOx from traffic during infancy), and
26.0 mg/m3 between 7 and 8 years of age (here defined as current
NOx from traffic). Current dietary folate intake (energy adjusted
intake at 8 years of age, in mg per day) was divided into quartiles
(Q1= 142.6 to ,192.7 mg per day, Q2= 192.7 to ,212.6,
Q3= 212.6 to ,235.3 mg per day, Q4= 235.3 to 401.6 mg per
day) before investigation. Current BMI (Body mass index at 8
years of age) was measured in kg/m2. Sampling season is the time
of the year when blood samples were collected at 8 years of age,
and were investigated in three-month seasons using January to
March as reference category.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts from Colo205 (colon adenocarcinoma, ATCC
CCL-222) and HEK293 (human embryonic kidney cells, ATCC
CRL-1573) cells were prepared according to standard protocols
[53]. Duplex probes encompassing the four sites CpG site 2
coinciding with rs2168890, CpG site 3, CpG site 8 coinciding with
rs2530547, and CpG site 9 coinciding with rs887020 in the
predicted NPSR1 promoter (Figure 1) were produced by annealing
oligonucleotide pairs specific for each allele at the polymorphic site
(2.5 mmol/l, probe sequences available upon request). The four
sites were chosen according to the central location of the CpG site
in relation to binding of the transcription factor and the value of
the transcription factor itself in relation to NPSR1 and/or asthma.
Binding reactions were performed in 25 mM HEPES pH 7.9,
150 mM KCl, 10% glycerol and 5 mM dithiothreitol, with 3 mg
nuclear extract, approximately 0.5 ng [a-32P] Klenow-labeled
probe and 3 mg poly dI-dC in a total volume of 20 mL.
Polyacrylamide (6%) gels were run in 0.56 tris-borate-EDTA at
4uC for 3 h at 300 V, dried, and autoradiographed to visualize
DNA protein complexes. Experiments were repeated three times
for each nuclear cell extract (Colo205 and HEK293). Both cell
extracts gave similar results and data shown is a representative gel
from the Colo205 analyses.
Isolated cell types from blood
Peripheral blood, 450 ml, was collected from six healthy adult
male blood donors, age 38613.6 years as described elsewhere
[25]. Briefly, whole blood, peripheral blood mononuclear cells
(PBMC), CD4+ T cells, CD8+ T-cells, CD56+ NK cells, CD19+ B
cells, CD14+ monocytes, granulocytes, neutrophils and eosinophils
were isolated. PBMC and granulocytes were isolated using Ficoll-
Paque PlusTM (GE Healthcare, Sweden). Magnetic-activated cell
sorting (MACS, Miltenyi Biotech, Germany) was used to obtain T
cells, B cells, monocytes, and NK cells from the PBMC:s and
neutrophils and eosinophils from the granulocyte containing
pellet. Cell purities were controlled by fluorescence activated cell
sorting (FACS) and ranged from lowest 81.8618.8% for
eosinophils to highest 97.861.7% for neutrophils. DNA was
extracted from cells using QIAmp DNA Micro Kit (QIAGEN,
Germany). 500 ng DNA was bisulfite treated using EZ-96 DNA
Methylation Kit (Zymo Research Corporation, USA) according to
the manufacturer’s instructions, and analyzed on the Illumina
Infinium 450K Bead array.
SNP genotyping
Primers for multiplex PCR and extension reactions were
designed by the SpectroDesigner software (Sequenom GmbH,
San Diego, CA, USA). All primer sequences are available on
request. PCR and extension reactions were performed according
to the manufacturer’s standard protocols. The SNP analysis in the
BAMSE samples was performed by MALDI-TOF mass spec-
trometry (matrix-assisted laser desorption/ionisation-time of flight;
Sequenom GmbH). Each assay was validated using a set of 14 trios
families, in total 42 individuals. Genotype data from these
individuals are available through the HapMap consortium
(http://hapmap.ncbi.nlm.nih.gov/). Concordance analyses with
the HapMap data as well as analysis of the parent-offspring-
compatibility with the produced genotypes were performed. No
significant deviation from Hardy-Weinberg equilibrium (P.0.05
using x2 test) was seen for any of the SNPs and the average
genotyping success rate was .95%. BIOAIR samples were
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genotyped using TaqMan allelic discrimination on the ABI Prism
7500 detection system according to the manufacturer’s protocol
(Assays used: C__16245540_10, C__16245541_10,
C___2959938_10, and C__2959937_10, Applied Biosystems,
CA, USA). Reruns of a small set of samples for all four genotypes
showed 100% success rate.
DNA methylation
The promoter region [24] used for primer design contained 12
CpG sites and four of these were affected by polymorphisms
(rs2168891 affecting CpG site 1, rs2168890 affecting CpG site 2,
rs2530547 affecting CpG site 8 and rs887020 affecting CpG site 9,
Figure 1). As a quality check for the methylation pattern in the
promoter of NPSR1, a second region with a predicted CTCF
binding site which is of interest for DNA methylation was chosen
for analysis in the intron 4 region. This region constituted 1053 bp
(NCBI36, chr7:34829940–34830992) and contained 11 CpG sites
(Figure S2). Two sites, CpG site 2 and 5, were affected by
polymorphism (rs17199818 and rs17199853, respectively). Primers
for the regions were designed using EpiDesigner (www.
epidesigner.com, Sequenom, CA, USA, Table S2). One mg of
DNA obtained from peripheral blood cells was modified by
sodium bisulfite using the EZ DNA MethylationTM Kit (Zymo
Research, CA, USA). Sodium bisulfite DNA was analysed using
EpiTYPER according to manufacturer’s recommendations &
protocol [26]. All EpiTYPER designs were quality tested by
analysing standard curves with methylated and unmethylated
DNA mixed in ratios resulting in 0%, 25%, 50%, 75%, and 100%
methylated DNA. This information resulted in the exclusion of
CpG site 7 in the promoter region and CpG site 5 in the CTCF
binding region from further analyses due to poor estimation of
DNA methylation (Figure S3). All samples were distributed
randomly on all plates based on disease phenotype, samples were
analysed in duplicates and samples with a standard deviation
above 0.3 were removed from further analysis. Two CpG sites
(CpG site 5 and 8 in the promoter) were included in two separate
designs and showed similar methylation levels for both assays
(Table S1). A quick analysis of the intron 4 region revealed a
similar pattern of DNA methylation compared to the promoter
region. No differences in DNA methylation based on respiratory
phenotype were found and therefore, this region was not studied
further.
Statistical analyses
None of the continuous variables deviated from normal
distribution including DNA methylation levels (Figure S4). For
basic comparisons of clinical characteristics, DNA methylation in
relation to asthma and other obstructive airway disease and
genotype effects on DNA methylation, Analysis of variance
(ANOVA) when considering three groups or Student’s T-test
when considering two groups were used. Distribution regarding
genotype and gender was compared using chi square test.
For the investigation of promoter methylation status and asthma
and other obstructive airway disease in the larger selection of
samples from the BIOAIR study (n= 171) and the BAMSE cohort
(n = 546), crude and adjusted linear regression model was used
(methylation levels as a continuous outcome). In the BIOAIR
analyses, the linear regression models were adjusted for the
potential confounders gender, age and country of origin for all
variables analysed. Linear regression analyses performed for the
BAMSE data were adjusted for the potential confounders gender,
age at blood sampling and plate used for sodium-bisulfite
treatment. For the investigation of DNA methylation status and
the effect of exposure to environmental factors linear regression
models were used adjusting for gender, age at blood sampling and
plate used for sodium-bisulfite treatment. For analyses of air
pollution effects, adjustment for municipality was also done. In
addition, adjustment for all the other exposure variables analyzed
in Table 5 did not change the results; neither did adjustment for
doctor’s diagnosis of asthma (ever) up to 8 years of age. STATA
(StataCorp LP, TX, USA) was used for all statistical analyses.
Supporting Information
Figure S1 The levels of DNA methylation (%) for each CpG site
studied in relation to age in years (dot blots, left column of graphs)
or material (box plots, right column of graphs). Dots with green
color in the box plot defines mild outliers (values that are under
three interquartile range (IQR) from the 25th and 75th percentiles)
and red dots defines severe outliers (values that are outside of three
IQR:s from the 25th and 75th percentiles). BAMSE - Swedish
abbreviation for Children Allergy Environment Stockholm
Epidemiology, BIOAIR - the BIOmarkers of severe chronic
AIRways disease.
(PDF)
Figure S2 The genetic sequence for the regions defined to bind
CTCF in intron 4 of Neuropeptide S Receptor 1 (NPSR1) gene.
Yellow regions indicate the CpG sites and red nucleotides indicate
genetic variants.
(PDF)
Figure S3 Standard curves obtained from the EpiTYPER
analysis of bisulfite treated samples. We designed three assays in
order to cover the Neuropeptide S Receptor 1 (NPSR1) gene
promoter region. CpG site 5 and CpG site 8 are covered by two
designs. CpG site 7 failed the validation and was excluded from
analysis.
(PDF)
Figure S4 The CpG sites analyzed showed normal distribution.
Data is displayed via histogram plots in the left column of graphs
and via probability plots in the right column of graphs.
(PDF)
Figure S5 DNA methylation levels (%) in the NPSR1 promoter
region in blood cells from six healthy adult male blood donors (age
38613.6 years). DNA methylation was analyzed using EpiTYPER
and the designs provided (Table S2).
(PDF)
Table S1 DNA methylation (%) in the Neuropeptide S Receptor
1 (NPSR1) gene analyzed using EpiTYPER in two two well
characterized cohorts that offer unique opportunities to investigate
genetics and epigenetics in relation to respiratory disease
phenotypes and environmental exposures; the BIOAIR study of
severe asthma in adults and the Swedish birth cohort BAMSE.
(PDF)
Table S2 EpiTYPER primer sequences for the Neuropeptide S
receptor 1 (NPSR1) gene.
(PDF)
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